$CLRB
Cellectar Biosciences, Inc.
Nasdaq · Healthcare · Pharmaceutical Preparations · Florham Park, NJ
CLRB chart
What traders are saying about $CLRB
Latest postsCellectar Biosciences, Inc. news
- Cellectar Biosciences (CLRB) Set to Report Q3 Earnings Amid Cont
GuruFocus ·
- Cellectar Biosciences, Inc. (CLRB) Seasonal returns chart
Yahoo Finance UK ·
- Cellectar BioSciences (CLRB.US) will release its financial report before the market opens on November 10.
Moomoo ·
- Cellectar Biosciences Announces Updated Clinical Data and Phase 3 Trial Design for Iopofosine I 131 in Waldenstro¨m Macroglobulinemia
www.marketscreener.com ·
- Cellectar Biosciences to Present Three Posters Highlighting Durable Clinical Activity of Iopofosine I 131 in Waldenström Macroglobulinemia at the American Society of Hematology Annual Meeting and Exposition
Yahoo Finance ·
- A cancer study found longer responses among patients with only two prior therapies
Stock Titan ·
- Cellectar Biosciences to Present Three Posters Highlighting
GlobeNewswire ·
- Cellectar Biosciences shows durable responses o...
Pluang ·
- Cellectar Biosciences to Report Third Quarter Financial Results and Host a Conference Call on Tuesday, November 10, 2026
Yahoo Finance ·
- Cellectar Biosciences Reports Case Study Highlighting Complete Response Lasting More Than Eight Years in Heavily Pretreated DLBCL Patient Treated with Iopofosine I 131
Yahoo Finance ·
- Cellectar Biosciences Presents Compelling Efficacy Data from Phase 2b CLOVER WaM Subset Analysis of Iopofosine I 131 in Patients Relapsed/Refractory to BTK Inhibitor Therapy at the International Workshop for Waldenström Macroglobulinemia
Yahoo Finance ·
- Cellectar Biosciences to Present Compelling Efficacy Data from Phase 2 CLOVER WaM Subset Analysis of Iopofosine I 131 in Patients Refractory/Resistant to BTK Inhibitor Therapy at International Workshop for Waldenström Macroglobulinemia
Yahoo Finance ·
Cellectar Biosciences, Inc. key financials
| USD | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|
| Net income | -$21.8M | -$44.6M | -$38.0M | -$31.8M |
| Diluted EPS | $-8.35 | $-41.89 | $-3.50 | $-4.51 |
| Total assets (year end) | $15.0M | $25.5M | $12.1M | $21.6M |
| Cash and equivalents (year end) | $13.2M | $23.3M | $9.6M | $19.9M |
Calendar-year figures as reported to the SEC in XBRL filings.
Recent SEC filings
About Cellectar Biosciences, Inc.
- Ticker
- CLRB (Nasdaq)
- Industry
- Pharmaceutical Preparations
- Headquarters
- Florham Park, NJ
- Incorporated in
- DE
- Fiscal year end
- December 31
- SEC CIK
- 1279704
- Former names
- NOVELOS THERAPEUTICS, INC., COMMON HORIZONS INC
Frequently asked questions
What exchange is Cellectar Biosciences, Inc. listed on?
Cellectar Biosciences, Inc. trades on the Nasdaq under the ticker symbol CLRB.
What industry is Cellectar Biosciences, Inc. in?
Cellectar Biosciences, Inc. is classified by the SEC under "Pharmaceutical Preparations", part of the Healthcare sector on StockTweeting.
Where is Cellectar Biosciences, Inc. headquartered?
Cellectar Biosciences, Inc.'s business address on file with the SEC is in Florham Park, NJ.
When does Cellectar Biosciences, Inc.'s fiscal year end?
Cellectar Biosciences, Inc.'s fiscal year ends on December 31.